Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q3 FY24 results · Oct–Dec 2023
Marksans Pharma reported revenue from operations of ₹586.13 crore (up 22.2% from Q3 FY23) and net profit of ₹82.97 crore (up 33.2% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 586.13 | 479.83 | +22.2% | 531.24 | +10.3% |
| Other income | 4.80 | 17.65 | −72.8% | 19.00 | −74.7% |
| Total income | 590.93 | 497.48 | +18.8% | 550.23 | +7.4% |
| Profit before tax | 112.66 | 79.20 | +42.2% | 113.77 | −1.0% |
| Net profit for the period | 82.97 | 62.31 | +33.2% | 83.85 | −1.1% |
| Attributable to shareholders of the company | 83.23 | 63.41 | +31.3% | 83.52 | −0.3% |
| EPS, basic (₹) | 1.84 | 1.56 | not comparable | 1.84 | +0.0% |
| Net margin (%) | 14.2 | 13.0 | 15.8 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 241.36 | 172.75 | +39.7% | 204.67 | +17.9% |
| Other income | 1.32 | 15.71 | −91.6% | 15.93 | −91.7% |
| Total income | 242.69 | 188.46 | +28.8% | 220.60 | +10.0% |
| Profit before tax | 34.60 | 34.50 | +0.3% | 44.50 | −22.3% |
| Net profit for the period | 25.29 | 25.62 | −1.3% | 31.29 | −19.2% |
| EPS, basic (₹) | 0.56 | 0.63 | not comparable | 0.69 | −18.8% |
| Net margin (%) | 10.5 | 14.8 | 15.3 |
Consolidated
- Filed with BSE
- 14 Feb 2024, 12:31 IST
- Board meeting
- 13 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Feb 2024, 12:31 IST
- Board meeting
- 13 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE